Cargando…

No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids

Unlike cytotoxicity, haematological toxicity is a rare immune‐related adverse event that is occasionally irreversible and refractory. A 67‐year‐old man was diagnosed with advanced lung squamous cell carcinoma. After 41 cycles of nivolumab as third‐line chemotherapy, the patient developed severe neut...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanai, Osamu, Nakatani, Koichi, Fujita, Kohei, Okamura, Misato, Mio, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175720/
https://www.ncbi.nlm.nih.gov/pubmed/34123387
http://dx.doi.org/10.1002/rcr2.799
_version_ 1783703103500976128
author Kanai, Osamu
Nakatani, Koichi
Fujita, Kohei
Okamura, Misato
Mio, Tadashi
author_facet Kanai, Osamu
Nakatani, Koichi
Fujita, Kohei
Okamura, Misato
Mio, Tadashi
author_sort Kanai, Osamu
collection PubMed
description Unlike cytotoxicity, haematological toxicity is a rare immune‐related adverse event that is occasionally irreversible and refractory. A 67‐year‐old man was diagnosed with advanced lung squamous cell carcinoma. After 41 cycles of nivolumab as third‐line chemotherapy, the patient developed severe neutropenia and thrombocytopenia. The bone marrow biopsy and serum immunological tests indicated no evidence of bone marrow failure and suggested autoimmune mature blood cell destruction. After initiating treatment with prednisolone 50 mg orally and filgrastim 75 μg subcutaneously once daily, neutropenia and thrombocytopenia recovered within four and nine days, respectively. The filgrastim was discontinued four days later, and the corticosteroid was discontinued three months later; there has been no haemocytopenia recurrence since then. The patient has remained untreated for more than two years without progression of lung cancer. In conclusion, corticosteroids should be considered for the treatment of autoimmune haemocytopenia if refractory bone marrow dysplasia can be ruled out.
format Online
Article
Text
id pubmed-8175720
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-81757202021-06-11 No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids Kanai, Osamu Nakatani, Koichi Fujita, Kohei Okamura, Misato Mio, Tadashi Respirol Case Rep Case Reports Unlike cytotoxicity, haematological toxicity is a rare immune‐related adverse event that is occasionally irreversible and refractory. A 67‐year‐old man was diagnosed with advanced lung squamous cell carcinoma. After 41 cycles of nivolumab as third‐line chemotherapy, the patient developed severe neutropenia and thrombocytopenia. The bone marrow biopsy and serum immunological tests indicated no evidence of bone marrow failure and suggested autoimmune mature blood cell destruction. After initiating treatment with prednisolone 50 mg orally and filgrastim 75 μg subcutaneously once daily, neutropenia and thrombocytopenia recovered within four and nine days, respectively. The filgrastim was discontinued four days later, and the corticosteroid was discontinued three months later; there has been no haemocytopenia recurrence since then. The patient has remained untreated for more than two years without progression of lung cancer. In conclusion, corticosteroids should be considered for the treatment of autoimmune haemocytopenia if refractory bone marrow dysplasia can be ruled out. John Wiley & Sons, Ltd 2021-06-03 /pmc/articles/PMC8175720/ /pubmed/34123387 http://dx.doi.org/10.1002/rcr2.799 Text en © 2021 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Kanai, Osamu
Nakatani, Koichi
Fujita, Kohei
Okamura, Misato
Mio, Tadashi
No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids
title No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids
title_full No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids
title_fullStr No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids
title_full_unstemmed No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids
title_short No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids
title_sort no need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175720/
https://www.ncbi.nlm.nih.gov/pubmed/34123387
http://dx.doi.org/10.1002/rcr2.799
work_keys_str_mv AT kanaiosamu noneedtohesitateimmunerelatedneutropeniaandthrombocytopeniathatimprovedbycorticosteroids
AT nakatanikoichi noneedtohesitateimmunerelatedneutropeniaandthrombocytopeniathatimprovedbycorticosteroids
AT fujitakohei noneedtohesitateimmunerelatedneutropeniaandthrombocytopeniathatimprovedbycorticosteroids
AT okamuramisato noneedtohesitateimmunerelatedneutropeniaandthrombocytopeniathatimprovedbycorticosteroids
AT miotadashi noneedtohesitateimmunerelatedneutropeniaandthrombocytopeniathatimprovedbycorticosteroids